MINISTRY OF COMMERCE AND INDUSTRY
(Department of Commerce)
(DIRECTORATE GENERAL OF TRADE REMEDIES)
New Delhi, the 25th August, 2020
Subject : Final Findings in anti-dumping investigation concerning imports of “Choline Chloride in all forms” originating in or exported from China PR, Malaysia and Vietnam.
F. No. 6/18/2019-DGTR.—Having regard to the Customs Tariff Act, 1975 as amended from time to time (hereinafter also referred to as the Act) and the Customs Tariff (Identification Assessment and Collection of Anti-Dumping Duty on Dumped Articles and for Determination of injury) Rules, 1995 as amended from time to time (hereinafter also referred to as the AD Rules or the Rules).
A. BACKGROUND OF THE CASE
1. The Designated Authority (herein after referred to as the Authority), received a written application from M/s Jubilant Life Sciences Ltd. (hereinafter also referred to as ―the Applicant‖ or ―the Domestic Industry‖) in accordance with the Act and the Rules for imposition of Anti-dumping duty on imports of “Choline Chloride in all its forms‖ (hereinafter also referred to as ―the product under consideration‖ or ―PUC‖ or ―subject goods‖) from People‘s Republic of China, Malaysia and Vietnam (hereinafter also referred to as the ―subject countries‖) alleging dumping and consequent injury and requested for levy of anti-dumping duty on the imports of the subject goods from the above subject countries.
2. The Authority, on the basis of sufficient prima-facie evidence submitted by the Applicant, issued a public notice vide Notification No. 6/18/2019- DGTR dated 1st October, 2019, published in the Gazette of India, Extraordinary, initiating anti-dumping investigation concerning imports of the subject goods, originating in or exported from the subject countries, in accordance with the sub-Rule 6(1) of the Rules, to determine the existence, degree and effect of alleged dumping and to consider recommendation of the anti-dumping duty, if any.
3. The procedure described herein below has been followed by the Authority with regard to the subject investigation:
a. The Authority notified the Embassies of the subject countries in India about the receipt of the antidumping application before proceeding to initiate the investigation in accordance with Rule 5(5) of the Rules.
b. The Authority issued a public notice vide its initiation notification dated 1st October 2019 published in the Gazette of India Extraordinary, initiating anti-dumping investigation concerning imports of the subject goods from subject countries.
c. The Authority, in terms of Rule 6(2) of the AD Rules, sent a copy of the public notice containing initiation notification to the Embassies of subject countries in India, known producers/exporters from the subject countries, known importers/ users and the domestic industry as well as other domestic producers as per the addresses made available in the application and requested them to make their views known in writing within the time limit prescribed in the initiation notification.
d. The Authority, in accordance with Rule 6(3) of the Rules, also forwarded a copy of the nonconfidential version of the application to known producers/ exporters from the subject countries, the Governments of the subject countries through their respective Embassies in India, the known importers/ users in India and other Indian producers as per the addresses made available in the application and requested them to make their views known in writing within 40 days from the date of issue of letter by the Authority intimating the initiation of the investigation. A copy of the non-confidential version of the application was also made available in the public file and provided to other interested parties, if requested in writing.
e. The Authority, in accordance with Rule 6(4) of the Rules, sent a notice containing Exporter‘s Questionnaire to the following known producers/ exporters calling for the relevant information in the form and manner prescribed:
i. M/s Cangzhou Dazheng Animal Medicine Co.,Ltd, China
ii. M/s Golden Higway Chemicals Ltd., China
iii. M/s Hebei Dahe International Trade Co. Ltd., China
iv. M/s Hubei Maxpharm Industries Co. Ltd.
v. M/s Liaonig Biochem Co. Ltd. China
vi. M/s Qingdao Good Prosper Imp. & Exp. Co. Ltd., China
vii. M/s Qingdao KFP Import & Export Co. Ltd., China
viii. M/s Shandong Aocter Chemical Co., Ltd. China
ix. M/s Shandong Jujia Biotechnology Co., Ltd., China
x. M/s Shandong NB Technology Co. Ltd. China
xi. M/s Shanghai Brightol International Co., Ltd., China
xii. M/s Taminco Choline Chloride, China
xiii. M/s Wuhan Xinxinjiali Biotechnology Co. Ltd, China
i. M/s Uni Pharma FZC (Malaysia) Sdn, Malaysia
i. M/s GHW (Vietnam) Co Ltd, Vietnam
ii. An Huy Company Limited, Vietnam
f. In response, the following exporters/producers from the subject countries filed exporter‘s questionnaire response:
i. M/s GHW (Vietnam) Co Ltd, Vietnam
ii. M/s GHW Holding Company, Hong Kong
g. The Authority, in accordance with Rule 6(4) of the Rules, also sent a notice containing Importer‘s Questionnaire to the following known importers/users of subject goods in India calling for necessary information in the form and manner prescribed:
i. M/s Nuovomondo Chemicals Pvt Ltd, Mumbai
ii. M/s Vetadd Nutrients Private Limited, Punjab
iii. M/s Niswin Enterprises, Tamil Nadu
iv. M/s Global Health Care, Delhi
v. M/s Planet Vyapaar Private Limited, Delhi
vi. M/s Sheng Long Bio-Tech (India) Private Limited, Tamil Nadu
vii. M/s Uttara Impex Private Limited, Pune
viii. M/s B Vital Therapeutics Pvt Ltd, Telangana
h. In response, the following importers/users have responded and filed importer‘s questionnaire response: